Drug Profile
Foravirumab
Alternative Names: CL-184Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Crucell
- Developer Crucell; Sanofi
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rabies
Most Recent Events
- 01 Sep 2015 No recent reports of development identified - Phase-II for Rabies (Combination therapy, In adolescents, In children, Prevention) in Philippines (IM)
- 01 Sep 2015 No recent reports of development identified - Phase-II for Rabies (Combination therapy, Prevention, In volunteers) in USA (IM)
- 01 Sep 2015 No recent reports of development identified - Phase-II for Rabies (Prevention) in India (IM)